News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Acrux.
RELATED STOCKHEAD STORIES
News
Rise and Shine: What you need to know before the ASX opens
Stockhead TV
StockTalk: Drug delivery tech offers patients, investors massive upside
Health & Biotech
Drug delivery technology: How it works, and the ASX companies with plans to capitalise
Health & Biotech
All of 1300 Smiles’ Jobkeeper subsidy has gone on its dividend
Health & Biotech
Dr Boreham’s Crucible: Dimerix not putting all its eggs in one basket
News
ASX Small Cap Lunch Wrap: Who’s keeping it ‘briefs’ today?
News
10 at 10: These ASX stocks are back with a bang this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
The pandemic could be a watershed moment for wellness products
News
Lunchtime ASX small cap wrap: who’s leaping higher today
Health & Biotech
Acrux poked an $8.7bn bear and now it’s fighting back; shares drop 24pc
Health & Biotech
A year after cold shower Acrux rebuild gets underway with first generic drug
Health & Biotech
What’s next for Acrux after end of US Axiron deal
News
Valor flies, ZipTel fails in our weekly ASX small cap wrap
Health & Biotech
What’s next for Acrux after collapse of US deal prompts 30pc share price plunge
Health & Biotech
